The synthetic lethality specialist licenses in its second ADC in six months.

US approval gives Pfizer the first and second-line settings.

But, like Merck two weeks ago, GSK has failed to hit overall survival.

Investors will hope for a JP Morgan buying spree, while readouts could come from Kura, Allogene and MacroGenics.

Two Kelun ADCs and two actinium-based radioconjugates start phase 1.

Data deteriorate, leaving cash-strapped Affimed relying on a post-hoc analysis and higher dosing.